Cite
HARVARD Citation
Meric-Bernstam, F. et al. (n.d.). Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC). European journal of cancer. pp. S12-S13. [Online].